A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Mar 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called VX-264 for people with Type 1 Diabetes (T1D). The main goal is to find out if VX-264 is safe to use, how well it works, and how well patients can tolerate it. The trial is currently looking for participants aged 6 to 74 years who have been living with T1D for at least five years and are on stable diabetes treatment. Participants should have been using continuous glucose monitoring (CGM) for at least four weeks before joining and be willing to continue using it throughout the study.

If you decide to take part in this trial, you will receive regular check-ups to monitor your health and how your body responds to the treatment. It’s important to note that if you have had a previous islet cell transplant, organ transplant, or cell therapy, you may not be eligible for this study. This trial could provide valuable information about a potential new treatment for T1D, which could benefit many people in the future.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Clinical history of T1D with greater than or equal to (\>=) 5 years duration
• • Participant is on a stable diabetic treatment
• • Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
• Key Exclusion Criteria:
• • Prior islet cell transplant, organ transplant, or cell therapy
• • Other protocol defined Inclusion/Exclusion criteria may apply.